Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.54 |
| ▸ | CHRNG | P07510 | 1/20 | 0.54 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.54 |
| ▸ | CHRND | Q07001 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8552509 | 1.00 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1220344 | 1.00 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL12375141 | 1.00 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7411707 | 0.98 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7412690 | 0.98 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7472810 | 0.98 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL15481770 | 0.90 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL21845171 | 0.90 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL27083284 | 0.90 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA3CHRNB4 | |
| Hydrochloric Acid SCHEMBL21806836 | 0.88 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNA3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252605-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTE RECH MED (FR) | 2018-06-13 | — | — | EP | disclosed |
| EP-2841402-B1 | LABELLED QUINOXALINE DERIVATIVES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-11-30 | — | — | EP | disclosed |
| US-9125937-B2 | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9029557-B2 | Labeled A4B2 ligands and methods therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150079000-A1 | Labelled Quinoxaline Derivatives as Multimodal Radiopharmaceuticals and Their Precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-03-19 | — | — | US | disclosed |
| US-20140050663-A1 | Labeled A4B2 Ligands and Methods Therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-20 | — | — | US | disclosed |
| EP-2657213-A1 | Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors | Institut National de la Santé et de la Recherche Medicale (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-8378109-B2 | Labeled ALPHA4BETA2 ligands and methods therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-02-24 | — | — | US | disclosed |
| WO-2010018218-A2 | IMPROVED FLUORIDATION OF IODONIUM SALTS | GE HEALTHCARE LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| US-7642373-B2 | Forming for example [18F]-dopamine or [18F]-uracil via reaction of iodonium salt precursor, where use of free radical scavenger improves yield of aryl fluoride | GE HEALTHCARE LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-20090297443-A1 | Labeled ALPHA4BETA2 Ligands and Methods Therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2119690-A1 | Radiolabelled MMP selective compounds | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2009-11-18 | — | — | EP | disclosed |
| EP-2085390-A1 | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-08-05 | — | — | EP | disclosed |
| EP-1697279-B1 | RADICAL TRAP IN FLUORIDATION OF IODINIUM SALT | GE HEALTHCARE LTD (GB) | 2008-09-24 | — | — | EP | disclosed |
| EP-1193253-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACIDS | KANEKA CORP (JP) | 2008-06-25 | — | — | EP | disclosed |
| WO-2006086068-A1 | LABELED ALPHA-4-BETA-2 LIGANDS AND METHODS THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-0846114-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1996040682-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079000-A1 | Labelled Quinoxaline Derivatives as Multimodal Radiopharmaceuticals and Their Precursors | HRH3, SSTR3, MC3R | CHRNB2 1038/4885CHRNA4 2153/4885CHRNA3 553/4885 |
| US-20140050663-A1 | Labeled A4B2 Ligands and Methods Therefor | CHRNB1, CHRNB4, CHRNB2 | CHRNB2 3/4885CHRNA4 7/4885CHRNA3 17/4885 |
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | CBR3, ADRB3, HRH4 | CHRNB2 664/4885CHRNA4 1468/4885CHRNA3 925/4885 |
| US-20090297443-A1 | Labeled ALPHA4BETA2 Ligands and Methods Therefor | CHRNE, CHRNB1, CHRNB4 | CHRNB2 4/4885CHRNA4 6/4885CHRNA3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.